David A. Rudnick
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
David A. Rudnick has a total of 163 co-authors. Here are the top co-authors by number of shared publications:
Jiansheng Huang
Department of Pediatrics, Washington University School of Medicine, St. Louis, USA
11 shared publicationsAlexander Weymann
Departments of Pediatrics, Washington University School of Medicine, St. Louis, MO
5 shared publicationsVered Gazit
Departments of Pediatrics, Washington University School of Medicine, St. Louis, MO
5 shared publicationsEric Hartman
Department of Pediatrics, Washington University School of Medicine, St. Louis, MO
4 shared publications- Jeffrey Teckman
Department of Pediatrics, Saint Louis University School of Medicine, Cardinal Glennon Children's Medical Center, Saint Louis, MO, USA
4 shared publications - Philip Rosenthal
Pediatrics and Surgery University of California San Francisco San Francisco
4 shared publications
Latest Publications
- Open Access
- 27 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
The polymerized protein response (PPR) is activated by genetic variants that polymerize in the ER and is mediated by NFκBp50
In previous studies we have shown that accumulation of the polymerogenic variant ATZ that causes α1-antitrypsin deficiency (ATD) activates NFκB DNA binding. Here we discovered that this response, which we are naming the polymerized protein response (PPR), is characterized by NFκB p50 homodimers, distinct from the p50/p65 heterodimers in the canonical NFκB inflammatory response and the unfolded protein response (UPR). The PPR is also activated by other disease associated variants that polymerize in the ER whereas disease-associated variants that do not form polymers activate p50/p65 heterodimers and UPR. The PPR elicits a unique gene expression profile, including changes that stabilize p50 homodimers in cytoplasm and nucleus. The PPR is blocked by specific genetic substitutions within the luminal and cytosolic domains of Derlin-2 providing evidence that the ERAD retrotranslocation complex is a proximal transducer of this signaling mechanism. We hypothesize that the PPR is a proteostasis response pathway complementary to the UPR, designed to protect the cell from the specific proteotoxic effects of polymers that form aberrantly in the ER.
- 27 April 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessThe polymerized protein response (PPR) is activated by genetic variants that polymerize in the ER and is mediated by NFκBp50
In previous studies we have shown that accumulation of the polymerogenic variant ATZ that causes α1-antitrypsin deficiency (ATD) activates NFκB DNA binding. Here we discovered that this response, which we are naming the polymerized protein response (PPR), is characterized by NFκB p50 homodimers, distinct from the p50/p65 heterodimers in the canonical NFκB inflammatory response and the unfolded protein response (UPR). The PPR is also activated by other disease associated variants that polymerize in the ER whereas disease-associated variants that do not form polymers activate p50/p65 heterodimers and UPR. The PPR elicits a unique gene expression profile, including changes that stabilize p50 homodimers in cytoplasm and nucleus. The PPR is blocked by specific genetic substitutions within the luminal and cytosolic domains of Derlin-2 providing evidence that the ERAD retrotranslocation complex is a proximal transducer of this signaling mechanism. We hypothesize that the PPR is a proteostasis response pathway complementary to the UPR, designed to protect the cell from the specific proteotoxic effects of polymers that form aberrantly in the ER.
- 2 April 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (6) , e70301
Therapy‐Associated Polyposis in Pediatric Cancer Survivors
Childhood cancer survivors face lifelong risks requiring ongoing monitoring. We report three cases of survivors who subsequently developed colon polyps in their teens or twenties within 10 years of completing cancer treatment. They presented with gastrointestinal symptoms, leading to early colonoscopies revealing tubular adenomas and other polyps. None had a family history of colon cancer or positive germline testing. Two had a history of astrocytoma, and one a history of relapsed T‐cell acute lymphoblastic leukemia; all had high cyclophosphamide equivalent doses (CED) of chemotherapy, and some received radiation. These observations suggest a diagnosis of therapy‐associated polyposis (TAP) linked to alkylating agents in addition to radiation and the need for heightened clinical awareness of TAP in cancer survivors.
- 2 April 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (6) , e70301
Therapy‐Associated Polyposis in Pediatric Cancer Survivors
Childhood cancer survivors face lifelong risks requiring ongoing monitoring. We report three cases of survivors who subsequently developed colon polyps in their teens or twenties within 10 years of completing cancer treatment. They presented with gastrointestinal symptoms, leading to early colonoscopies revealing tubular adenomas and other polyps. None had a family history of colon cancer or positive germline testing. Two had a history of astrocytoma, and one a history of relapsed T‐cell acute lymphoblastic leukemia; all had high cyclophosphamide equivalent doses (CED) of chemotherapy, and some received radiation. These observations suggest a diagnosis of therapy‐associated polyposis (TAP) linked to alkylating agents in addition to radiation and the need for heightened clinical awareness of TAP in cancer survivors.
- Open Access
- 31 March 2026
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (4)
CD8 TRM-like T cells expressing perforin and IFN-γ define a pediatric activated T-cell acute liver failure endotype
Background: Activated T-cell pediatric acute liver failure (TC-PALF) is the most common cause of non-acetaminophen PALF, with poor transplant-free survival. Livers in TC-PALF are infiltrated by effector cytotoxic T lymphocytes with markers of tissue-resident memory function (CD8 Trm) and an interferon gamma (IFNγ) transcriptional signature. The PALF-Immune Response Network (PALF-IRN) and the prospective TReatment for ImmUne-Mediated PathopHysiology (TRIUMPH) clinical trial (NCT04862221) aim to characterize the TC-PALF immune pathology and utility of T-cell directed therapy to improve transplant-free survival. Methods: TRIUMPH patients with TC-PALF were compared with healthy children and disease controls utilizing multiparameter flow cytometry and 3′ single-cell RNA sequencing from peripheral blood mononuclear cells. TC-PALF patient serum was compared with healthy children and those with PALF from other causes, utilizing the Olink Inflammation I 384 protein assay. Results: Two distinct endotypes of TC-PALF were identified, which differed in flow cytometry CD8+ Perforin1 (Prf) expression and liver biopsy staining of Prf. TC-PALF patients with high CD8+ Prf (TC-PALF High Prf) had monocytosis, with a unique circulating CD8 IFNγ+ Trm-like population and IFNγ-responsive CD14/CD16 monocyte ligand–receptor interaction. TC-PALF patients with normal CD8+ Prf expression had hypergammaglobulinemia, an increase in class-switched B-cells, and a decrease in serum inflammatory proteins associated with myeloid activation. Conclusions: TC-PALF high Prf patients have a unique circulating CD8+ IFNγ+ Trm-like population accompanied by monocyte proliferation and activation. Further understanding of the role of IFNγ in TC-PALF High Prf may provide a therapeutic target for this endotype to improve transplant-free survival. Export
- 31 March 2026
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (4)
Open AccessCD8 TRM-like T cells expressing perforin and IFN-γ define a pediatric activated T-cell acute liver failure endotype
Background: Activated T-cell pediatric acute liver failure (TC-PALF) is the most common cause of non-acetaminophen PALF, with poor transplant-free survival. Livers in TC-PALF are infiltrated by effector cytotoxic T lymphocytes with markers of tissue-resident memory function (CD8 Trm) and an interferon gamma (IFNγ) transcriptional signature. The PALF-Immune Response Network (PALF-IRN) and the prospective TReatment for ImmUne-Mediated PathopHysiology (TRIUMPH) clinical trial (NCT04862221) aim to characterize the TC-PALF immune pathology and utility of T-cell directed therapy to improve transplant-free survival. Methods: TRIUMPH patients with TC-PALF were compared with healthy children and disease controls utilizing multiparameter flow cytometry and 3′ single-cell RNA sequencing from peripheral blood mononuclear cells. TC-PALF patient serum was compared with healthy children and those with PALF from other causes, utilizing the Olink Inflammation I 384 protein assay. Results: Two distinct endotypes of TC-PALF were identified, which differed in flow cytometry CD8+ Perforin1 (Prf) expression and liver biopsy staining of Prf. TC-PALF patients with high CD8+ Prf (TC-PALF High Prf) had monocytosis, with a unique circulating CD8 IFNγ+ Trm-like population and IFNγ-responsive CD14/CD16 monocyte ligand–receptor interaction. TC-PALF patients with normal CD8+ Prf expression had hypergammaglobulinemia, an increase in class-switched B-cells, and a decrease in serum inflammatory proteins associated with myeloid activation. Conclusions: TC-PALF high Prf patients have a unique circulating CD8+ IFNγ+ Trm-like population accompanied by monocyte proliferation and activation. Further understanding of the role of IFNγ in TC-PALF High Prf may provide a therapeutic target for this endotype to improve transplant-free survival. Export
- Open Access
- 30 December 2023
- Published by Elsevier in Cellular and Molecular Gastroenterology and Hepatology
- Vol. 17 (3) , 501-502
New Insights About Epigenetic Mechanisms That Influence Risk of Transgenerational Fatty Liver Disease
- 30 December 2023
- Published by Elsevier in Cellular and Molecular Gastroenterology and Hepatology
- Vol. 17 (3) , 501-502
Open AccessNew Insights About Epigenetic Mechanisms That Influence Risk of Transgenerational Fatty Liver Disease
- 24 June 2022
- Published by Elsevier in Clinics in Liver Disease
- Vol. 26 (3) , 461-471
An Update on Pediatric Acute Liver Failure
- 24 June 2022
- Published by Elsevier in Clinics in Liver Disease
- Vol. 26 (3) , 461-471
An Update on Pediatric Acute Liver Failure
- 19 April 2022
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 74 (6) , 750-756
Outcomes Analyses of Pediatric Acute Liver Failure Subjects Listed for Liver Transplantation
Background: We characterized recent outcomes in US pediatric acute liver failure (PALF) subjects listed for liver transplantation (LT) using the Scientific Registry of Transplant Recipients (SRTR) database.Methods: Pediatric subjects listed for LT from 2002 to 2015 were assigned to the “PALF” group based on status 1/1A listing, INR >2, no hepatic artery thrombosis, and no primary graft nonfunction (N = 397). Subjects were assigned to the “non‐PALF” group if listed with any status other than 1/1A (N = 4509).Results: The PALF group had more infants <3 months of age and males at listing for LT compared to the non‐PALF group. Two‐thirds of PALF subjects had an indeterminate etiology. LT waitlist survival was significantly worse in the PALF group compared to the non‐PALF group. Likelihood of removal from the LT waitlist for being “too sick” was higher, while that of removal for “spontaneous recovery” was lower in PALF subjects. Post‐LT short‐term (30 days) and long‐term (60 months) outcomes were also significantly worse in PALF versus non‐PALF subjects. PALF subjects who underwent living‐donor‐liver‐transplant (LDLT) had similar LT waitlist times and post‐LT survival compared to those undergoing deceased‐donor‐liver‐transplant (DDLT). Over the study period, we observed a decreased number of liver transplants, and increase in LT waitlist‐ and short‐term post‐LT‐survival in PALF subjects.Conclusion: LT waitlist and post‐LT outcomes are worse in PALF subjects compared to non‐PALF subjects. PALF subjects who undergo LDLT have similar waitlist times and post‐LT outcomes compared to those undergoing DDLT.
- 19 April 2022
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 74 (6) , 750-756
Outcomes Analyses of Pediatric Acute Liver Failure Subjects Listed for Liver Transplantation
Background: We characterized recent outcomes in US pediatric acute liver failure (PALF) subjects listed for liver transplantation (LT) using the Scientific Registry of Transplant Recipients (SRTR) database.Methods: Pediatric subjects listed for LT from 2002 to 2015 were assigned to the “PALF” group based on status 1/1A listing, INR >2, no hepatic artery thrombosis, and no primary graft nonfunction (N = 397). Subjects were assigned to the “non‐PALF” group if listed with any status other than 1/1A (N = 4509).Results: The PALF group had more infants <3 months of age and males at listing for LT compared to the non‐PALF group. Two‐thirds of PALF subjects had an indeterminate etiology. LT waitlist survival was significantly worse in the PALF group compared to the non‐PALF group. Likelihood of removal from the LT waitlist for being “too sick” was higher, while that of removal for “spontaneous recovery” was lower in PALF subjects. Post‐LT short‐term (30 days) and long‐term (60 months) outcomes were also significantly worse in PALF versus non‐PALF subjects. PALF subjects who underwent living‐donor‐liver‐transplant (LDLT) had similar LT waitlist times and post‐LT survival compared to those undergoing deceased‐donor‐liver‐transplant (DDLT). Over the study period, we observed a decreased number of liver transplants, and increase in LT waitlist‐ and short‐term post‐LT‐survival in PALF subjects.Conclusion: LT waitlist and post‐LT outcomes are worse in PALF subjects compared to non‐PALF subjects. PALF subjects who undergo LDLT have similar waitlist times and post‐LT outcomes compared to those undergoing DDLT.
- Open Access
- 15 March 2022
- Published by Elsevier in Gastroenterology
- Vol. 163 (1) , 270-284
Regulation of PGC1α Downstream of the Insulin Signaling Pathway Plays a Role in the Hepatic Proteotoxicity of Mutant α1-Antitrypsin Deficiency Variant Z
- 15 March 2022
- Published by Elsevier in Gastroenterology
- Vol. 163 (1) , 270-284
Open AccessRegulation of PGC1α Downstream of the Insulin Signaling Pathway Plays a Role in the Hepatic Proteotoxicity of Mutant α1-Antitrypsin Deficiency Variant Z
- Open Access
- 10 September 2020
- Published by Wiley in PPAR Research
- Vol. 2020, 1-20
Diet Modifies Pioglitazone’s Influence on Hepatic PPARγ-Regulated Mitochondrial Gene Expression
Pioglitazone (Pio) is a thiazolidinedione (TZD) insulin-sensitizing drug whose effects result predominantly from its modulation of the transcriptional activity of peroxisome proliferator-activated-receptor-gamma (PPARγ). Pio is used to treat human insulin-resistant diabetes and also frequently considered for treatment of nonalcoholic steatohepatitis (NASH). In both settings, Pio’s beneficial effects are believed to result primarily from its actions on adipose PPARγ activity, which improves insulin sensitivity and reduces the delivery of fatty acids to the liver. Nevertheless, a recent clinical trial showed variable efficacy of Pio in human NASH. Hepatocytes also express PPARγ, and such expression increases with insulin resistance and in nonalcoholic fatty liver disease (NAFLD). Furthermore, mice that overexpress hepatocellular PPARγ and Pio-treated mice with extrahepatic PPARγ gene disruption develop features of NAFLD. Thus, Pio’s direct impact on hepatocellular gene expression might also be a determinant of this drug’s ultimate influence on insulin resistance and NAFLD. Previous studies have characterized Pio’s PPARγ-dependent effects on hepatic expression of specific adipogenic, lipogenic, and other metabolic genes. However, such transcriptional regulation has not been comprehensively assessed. The studies reported here address that consideration by genome-wide comparisons of Pio’s hepatic transcriptional effects in wildtype (WT) and liver-specific PPARγ-knockout (KO) mice given either control or high-fat (HFD) diets. The results identify a large set of hepatic genes for which Pio’s liver PPARγ-dependent transcriptional effects are concordant with its effects on RXR-DNA binding in WT mice. These data also show that HFD modifies Pio’s influence on a subset of such transcriptional regulation. Finally, our findings reveal a broader influence of Pio on PPARγ-dependent hepatic expression of nuclear genes encoding mitochondrial proteins than previously recognized. Taken together, these studies provide new insights about the tissue-specific mechanisms by which Pio affects hepatic gene expression and the broad scope of this drug’s influence on such regulation.
- 10 September 2020
- Published by Wiley in PPAR Research
- Vol. 2020, 1-20
Open AccessDiet Modifies Pioglitazone’s Influence on Hepatic PPARγ-Regulated Mitochondrial Gene Expression
Pioglitazone (Pio) is a thiazolidinedione (TZD) insulin-sensitizing drug whose effects result predominantly from its modulation of the transcriptional activity of peroxisome proliferator-activated-receptor-gamma (PPARγ). Pio is used to treat human insulin-resistant diabetes and also frequently considered for treatment of nonalcoholic steatohepatitis (NASH). In both settings, Pio’s beneficial effects are believed to result primarily from its actions on adipose PPARγ activity, which improves insulin sensitivity and reduces the delivery of fatty acids to the liver. Nevertheless, a recent clinical trial showed variable efficacy of Pio in human NASH. Hepatocytes also express PPARγ, and such expression increases with insulin resistance and in nonalcoholic fatty liver disease (NAFLD). Furthermore, mice that overexpress hepatocellular PPARγ and Pio-treated mice with extrahepatic PPARγ gene disruption develop features of NAFLD. Thus, Pio’s direct impact on hepatocellular gene expression might also be a determinant of this drug’s ultimate influence on insulin resistance and NAFLD. Previous studies have characterized Pio’s PPARγ-dependent effects on hepatic expression of specific adipogenic, lipogenic, and other metabolic genes. However, such transcriptional regulation has not been comprehensively assessed. The studies reported here address that consideration by genome-wide comparisons of Pio’s hepatic transcriptional effects in wildtype (WT) and liver-specific PPARγ-knockout (KO) mice given either control or high-fat (HFD) diets. The results identify a large set of hepatic genes for which Pio’s liver PPARγ-dependent transcriptional effects are concordant with its effects on RXR-DNA binding in WT mice. These data also show that HFD modifies Pio’s influence on a subset of such transcriptional regulation. Finally, our findings reveal a broader influence of Pio on PPARγ-dependent hepatic expression of nuclear genes encoding mitochondrial proteins than previously recognized. Taken together, these studies provide new insights about the tissue-specific mechanisms by which Pio affects hepatic gene expression and the broad scope of this drug’s influence on such regulation.
- 1 August 2019
- Published by Elsevier in The American Journal of Pathology
- Vol. 189 (8) , 1501-1504
Invasive Ductular Reaction
- 1 August 2019
- Published by Elsevier in The American Journal of Pathology
- Vol. 189 (8) , 1501-1504
Invasive Ductular Reaction
- 29 June 2017
- Published by Wolters Kluwer Health in Clinical Liver Disease
- Vol. 9 (6) , 138-140
Antifibrotic therapies in liver disease: Ready for primetime?
- 29 June 2017
- Published by Wolters Kluwer Health in Clinical Liver Disease
- Vol. 9 (6) , 138-140
Antifibrotic therapies in liver disease: Ready for primetime?